AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04069728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard explanation
Description: Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
Study NCT04640155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
Study NCT04640155 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular Diet
Description: Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
Study NCT03504722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
Study NCT03504722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
Study NCT01236378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
Study NCT03994731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV pegloticase 8 mg Q2W
Study NCT03994731 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegloticase
Description: IV pegloticase 8 mg Q2W
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral MTX 15 mg weekly
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral MTX 15 mg weekly
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo for MTX
Study NCT03994731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
Study NCT03994731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gout flare prophylaxis regimen
Description: Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gout flare prophylaxis regimen
Description: Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fexofenadine
Description: For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
Study NCT02769312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Theta burst transcranial magnetic stimulation
Study NCT02769312 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham Theta burst transcranial magnetic stimulation
Study NCT04818203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of Autologous Dermal Fibroblasts
Description: Dose: 1 x 10\^7 cells/1 mL/vial
Study NCT04818203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injection solution without clusters of autologous dermal fibroblasts
Study NCT01742416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Arterial cannulation facilitated by ultrasound.
Study NCT01742416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation Method
Description: Arterial cannulation by palpation method.
Study NCT00640406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Renal Stent plus Best Medical Treatment
Description: percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
Study NCT00640406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: best medical treatment for hypertension secondary to renal artery stenosis according to local standards
Study NCT00392756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone (GnRH)
Description: pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
Study NCT01861353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry-lingonberry juice
Study NCT03994731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
Study NCT03186001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Description: The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
Study NCT03042832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOCI
Description: Leadership development with coaching and organizational change support
Study NCT03042832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Based Webinar Leadership Training
Description: Internet Based Webinar Leadership Training
Study NCT01276808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic navigation PCI
Description: Magnetically navigated angioplasty wire technique
Study NCT01861353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
Study NCT01556230 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical intervention for CNFA
Description: (non-experimental) standard procedure
Study NCT01276808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: Conventional manual angioplasty wire percutaneous coronary intervention
Study NCT01556230 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy for CNFA
Description: (non-experimental) standard procedure
Study NCT00548483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone (Oradexon, Nederland)
Description: dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
Study NCT03597373 — intervention group
Intervention type: OTHER
Intervention: reintubation
Description: Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
Study NCT02806362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Tablet
Study NCT03337438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Feedback Intervention with Values
Description: The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
Study NCT03337438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Feedback Intervention Traditional
Description: This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
Study NCT03099902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function
Description: Spirometry test
Study NCT03099902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell DNA extraction
Description: GSTP1 and TNFa polymorphisms with PCR
Study NCT03099902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary testing
Description: Urinary nicotine and cotinine detection
Study NCT01829997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOss Bioactive 3D BVF
Description: nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
Study NCT02003677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
Study NCT02003677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01994707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02514681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01627015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified infant follow-on formula
Description: The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
Study NCT01994707 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deflated cuff on arm for 30 minutes.
Study NCT01960062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes software and device
Description: USB cord, CD-rom, and application to allow communication with provider
Study NCT02776540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
Study NCT02776540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: there's another group will receive 400 mg Aspirin
Study NCT00408551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given IV
Study NCT01627015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant follow-on formula
Description: Infants are fed a commercial follow-on formula
Study NCT00186017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine/Zyprexa
Description: Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
Study NCT00186017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine/Zyprexa
Description: Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
Study NCT03944655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strepsils Anaesthetic Formula
Description: Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
Study NCT03944655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clear Mint Drops
Description: Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
Study NCT00983853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir or matching placebo
Description: Tablet, Oral, 750 mg, q8h, 12 weeks
Study NCT00983853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir or matching placebo
Description: Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
Study NCT00983853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Subcutaneous injection, 180 μg, once weekly, 48 weeks
Study NCT00983853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (fixed dose)
Description: Tablet, Oral, 800 mg, b.i.d., 48 weeks
Study NCT00983853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (weight-based dose)
Description: Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
Study NCT03965442 — intervention group
Intervention type: DRUG
Intervention: Control
Description: Patients who underwent mastectomy under standard general anesthesia
Study NCT03965442 — intervention group
Intervention type: DRUG
Intervention: Esmolol
Description: Patients who underwent mastectomy under general anesthesia with esmolol infusion
Study NCT02081053 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System
Description: Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
Study NCT04113070 — intervention group
Intervention type: DEVICE
Intervention: Anthropometric measuring
Description: To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
Study NCT04113070 — intervention group
Intervention type: OTHER
Intervention: Growth environment evaluation
Description: The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
Study NCT03776305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
Study NCT01736540 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2\*, respectively).
Study NCT02475512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash wipes (3M)
Study NCT02475512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water and pH neutral soap
Study NCT01458054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
Description: GSK2336805 and Omeprazole
Study NCT01458054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Description: GSK2336805 and Ritonavir
Study NCT00897793 — intervention group
Intervention type: PROCEDURE
Intervention: venipuncture
Description: Venipuncture for blood samples. Samples will be tested for TGF-beta.
Study NCT00897793 — intervention group
Intervention type: RADIATION
Intervention: radiation therapy
Description: Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
Study NCT01370655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145
Study NCT00408551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00408551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00408551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00408551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01349530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating of usual care
Description: RESEARCH IN CURRENT CARE
Study NCT01349530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of CREATIF
Description: RESEARCH IN CURRENT CARE